Arcadia Biosciences Q1 revenue falls 8%, swings to loss

Arcadia Biosciences

14/05/2026 21:27

Overview

Wellness products maker's Q1 revenue fell 8% yr/yr, driven by prior-year reserve release

Co reported net loss compared to profit a year ago, reflecting warrant inducement loss and absence of prior-year gains

Zola coconut water unit volumes rose 18% yr/yr, and benefitted by price increase

Outlook

Company expects to launch a new product at major customers this fall

Arcadia remains focused on growing its Zola coconut water brand

Result Drivers

ZOLA VOLUME AND PRICE - Zola coconut water unit volumes rose 18% yr/yr and benefited from a price increase, boosting product sales

REVENUE RESERVE IMPACT - Revenue decline was mainly due to a $193,000 revenue reserve release in Q1 2025 that did not recur

ABSENCE OF PRIOR-YEAR GAINS - Operating expenses rose due to the absence of a $750,000 gain on patent portfolio sale and $1.0 mln gain from contingent consideration liability in Q1 2025

Company press release: ID:nGNXbrlsZj

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$1.10 mln
Q1 EPS
-$2.11
Q1 Net Income
-$4.39 mln
Q1 Operating Expenses
$1.88 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)